The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease
نویسنده
چکیده
The "therapeutic chelation" approach to treating Alzheimer's disease (AD) evolved from the metals hypothesis, with the premise that small molecules can be designed to prevent transition metal-induced amyloid deposition and oxidative stress within the AD brain. Over more than 20 years, countless in vitro studies have been devoted to characterizing metal binding, its effect on Aβ aggregation, ROS production, and in vitro toxicity. Despite a lack of evidence for any clinical benefit, the conjecture that therapeutic chelation is an effective approach for treating AD remains widespread. Here, the author plays the devil's advocate, questioning the experimental evidence, the dogma, and the value of therapeutic chelation, with a major focus on copper ions.
منابع مشابه
Commentary: The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer’s Disease
متن کامل
A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation.
The intersection of the amyloid cascade hypothesis and the implication of metal ions in Alzheimer's disease progression has sparked an interest in using metal-binding compounds as potential therapeutic agents. In the present work, we describe a prochelator SWH that is enzymatically activated by beta-secretase to produce a high affinity copper chelator CP. Because beta-secretase is responsible f...
متن کاملNeurodegenerative diseases and therapeutic strategies using iron chelators.
This review will summarise the current state of our knowledge concerning the involvement of iron in various neurological diseases and the potential of therapy with iron chelators to retard the progression of the disease. We first discuss briefly the role of metal ions in brain function before outlining the way by which transition metal ions, such as iron and copper, can initiate neurodegenerati...
متن کاملNew Ideas in Chelation Therapy
The cornerstone of the treatment of Wilson’s disease is a reduction of copper levels in vivo using the orallyadministered chelating agents D-penicillamine and trientine dihydrochloride. Patients with side-effects from receiving multiple blood transfusions for the amelioration of inherited anaemias are also successfully treated with chelating agents. Blood transfusion elevates these patients’ ir...
متن کاملCopper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
The amyloid hypothesis states that amyloid beta protein (Abeta) plays a major causal role in the onset of Alzheimer's disease. Toxicity of Abeta can be modified by metal ions. Two mechanisms by which such Abeta and metal ions could interact are by enhanced oxidative stress or by altered fibrillation. Specifically, Abeta fibrillation is increased by aluminum (Al) and copper (Cu) and Al also incr...
متن کامل